搜索
 >  其他蛋白>CD19>Human CD19 (20-291) Protein, His Tag

Human CD19 (20-291) Protein, His Tag

分子别名(Synonym)

CD19,B4,CVID3,MGC12802

表达区间及表达系统(Source)

Human CD19 (20-291), His Tag (CD9-H52H2) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).

Predicted N-terminus: Pro 20

蛋白结构(Molecular Characterization)

CD19(Pro 20 - Lys 291) P15391-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 32.0 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by reduced SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss is observed after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Human CD19 (20-291), His Tag (Cat. No. CD9-H52H2) SDS-PAGE gel

Human CD19 (20-291), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

活性(Bioactivity)

Human CD19 (20-291), His Tag (Catalog = CD9-H52H2) ELISA bioactivity

Immobilized FMC63 MAb at 2 μg/mL (100 μL/well) can bind Human CD19, His Tag (Cat. No. CD9-H52H2) with a linear range of 10-78 ng/mL (QC tested).

点击申请Protocol

 

CAR阳性表达率检测(Evaluation of CAR expression )

FACS Analysis of anti-CD19 CAR expression

CAR

293 cells were transfected with FMC63-scFv and RFP tag .  2x105 of the cells were first incubated with A. His Tag-protein control. B. Recombinant human CD19, His Tag (Cat. No. CD9-H52H2, 10ug/ml). C. Recombinant human CD19, His Tag (Cat. No. CD9-H52H2, 10ug/ml) and FMC63(Mouse anti-CD19 antibody). The FITC Anti-6xHis tag antibody was used to analyse with FACS. RFP was used to evaluate CAR(FMC63-scFv) expression and FITC was used to evaluate the binding activity  of recombinant human CD19, His Tag (Cat. No. CD9-H52H2) .

点击申请Protocol

 

背景(Background)

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

参考文献(References)

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.


货号/价格

CD9-H52H2-50ug / ¥3200

CD9-H52H2-500ug / ¥21100

文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-31604788(上海)
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
CD19靶点信息
英文全称:B-lymphocyte antigen CD19
中文全称:B淋巴细胞抗原CD19
种类:Homo sapiens
上市药物数量:3详情
临床药物数量:46详情
最高研发阶段:批准上市
查看更多
问题&评论

×
英文名称中文名称研发代码研发阶段公司最早商品名最早批准国家最早适应症最早批准公司最早批准日期适应症临床试验
BlinatumomabAMG-103; MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3批准上市安进BLINCYTOfda急性淋巴细胞白血病AMGEN2014-12-03急性淋巴细胞白血病详情
TisagenlecleucelCART-019; CART-19; CTL-019; LG-740批准上市宾夕法尼亚大学, 诺华急性淋巴细胞白血病详情
Axicabtagene ciloleucelFKC876; KTE-C19批准上市Cabaret Biotech, Kite Pharma, 复星医药B细胞淋巴瘤, 弥漫大B细胞淋巴瘤, 滤泡性淋巴瘤详情
英文名称研发代码研发阶段公司适应症临床试验
CD19 chimeric antigen receptor T cell therapy (Takara Bio)TBI-1501临床二期TaKaRa Bio, 斯隆-凯特琳癌症中心非霍奇金淋巴瘤
iPD1 CD19 eCAR-T therapy (Marino Biotechnology)临床一期北京马力喏生物科技有限公司, 北京大学B细胞淋巴瘤
Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source)临床一期Nonindustrial source非霍奇金淋巴瘤
SGN-CD19BSGN-CD19B临床一期Seattle Genetics非霍奇金淋巴瘤详情
Taplitumomab paptox临床三期University of Minnesota白血病
aCD19zaCD19z临床一期克里斯蒂NHS基金信托医院, Cellular Therapeutics非霍奇金淋巴瘤
C-CAR-011临床二期中国人民解放军总医院/解放军医学院, 西比曼生物科技(上海)有限公司淋巴细胞性白血病, 套细胞淋巴瘤, 弥漫大B细胞淋巴瘤, 白血病, 滤泡性淋巴瘤, 非霍奇金淋巴瘤
pCAR-19B临床申请重庆精准生物技术白血病
DT-2219-ARLAnti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219-ARL; OXS-1550; DT-2219ARL; DT-2219; IND-100780临床二期University of Minnesota, Oxis International, GT BiopharmaB细胞淋巴瘤, 白血病详情
Anti-CD22/CD19 monoclonal antibody-toxin conjugate临床一期德克萨斯大学西南医学中心, Galileo ResearchB细胞淋巴瘤, 急性淋巴细胞白血病
AUTO-1AUTO1; AUTO-1临床一期英国伦敦大学学院, Autolus伯基特淋巴瘤, 急性淋巴细胞白血病
CD19-CART临床二期上海恒润达生生物科技弥漫大B细胞淋巴瘤, 慢性淋巴细胞白血病, 滤泡性淋巴瘤, 急性淋巴细胞白血病详情
AFM-11AFM-11临床一期Affimed非霍奇金淋巴瘤详情
IM19CAR-T临床二期北京艺妙医疗科技白血病, 非霍奇金淋巴瘤详情
3rd-gen-CD19-CAR3rd-gen-CD19-CAR临床二期bluebird bio, 新基B细胞淋巴瘤, 白血病
MDX 1342MDX-1342临床一期Medarex慢性淋巴细胞白血病, 类风湿性关节炎详情
A-319A-319,A319临床申请健能隆医药B细胞淋巴瘤, 慢性淋巴细胞白血病, 急性淋巴细胞白血病
MOR-208MOR-208; MOR-00208; XENP-5574; XmAb-5574临床三期Xencor, MorphoSys慢性淋巴细胞白血病, 弥漫大B细胞淋巴瘤, 急性淋巴细胞白血病, 非霍奇金淋巴瘤详情
CD19 CAR-T (HuaDao CAR-Tcell)临床申请HuaDao CAR-Tcell急性淋巴细胞白血病, 非霍奇金淋巴瘤
JCAR-015JCAR-15; JCAR-015; 19-28z CAR T cells; 19-28z+ T cells; 19-28z-T-Cells临床二期弗莱德哈钦森癌症研究中心, Juno Therapeutics, 西雅图儿研所, 斯隆-凯特琳癌症中心, 新基, TaKaRa Bio急性淋巴细胞白血病, 非霍奇金B细胞淋巴瘤详情
InebilizumabMEDI-551; 16C4-aFuc; 74T7185BMM (UNII code)临床三期MedImmune弥漫大B细胞淋巴瘤, 多发性硬化症, 硬皮病, 视神经脊髓炎详情
HuCART19临床一期Kite Pharma, 美国国立癌症研究所B-细胞恶性肿瘤详情
Denintuzumab mafodotinSGN-19A; SGN-CD19A临床二期Seattle Genetics弥漫大B细胞淋巴瘤, 滤泡性淋巴瘤, 急性淋巴细胞白血病, 非霍奇金淋巴瘤详情
CTL-119CTL-119临床一期宾夕法尼亚大学, 诺华弥漫大B细胞淋巴瘤, 急性淋巴细胞白血病
Coltuximab ravtansineSAR-3419; huB4-DM4临床二期ImmunoGen, 赛诺菲弥漫大B细胞淋巴瘤, 急性淋巴细胞白血病详情
19-28z+19-28z+临床二期斯隆-凯特琳癌症中心, Dana-Farber Cancer Institute白血病
UCART-19UCART-19; S-68587临床一期Cellectis, 辉瑞, 施维雅慢性淋巴细胞白血病, 急性淋巴细胞白血病
CD19-CARCD19-CAR临床一期M.D. Anderson Cancer Center, Ziopharm Oncology, Intrexon Corporation白血病, 淋巴瘤
CD19.CAR-VSTCD19.CAR-VST临床一期贝勒医学院, 德克萨斯儿童医院, 卫理公会医院慢性淋巴细胞白血病, 急性淋巴细胞白血病, 非霍奇金淋巴瘤
CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology)临床申请上海优卡迪生物医药科技淋巴瘤
JWCAR-029JWCAR-029,JWCAR029; JWCAR 029临床申请上海明聚生物血液系统恶性肿瘤详情
JCAR-014JCAR-014临床二期弗莱德哈钦森癌症研究中心, Juno Therapeutics, 西雅图儿研所, 斯隆-凯特琳癌症中心, 新基慢性淋巴细胞白血病, 急性淋巴细胞白血病, 非霍奇金B细胞淋巴瘤详情
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology)临床二期河北森朗生物科技有限公司B细胞淋巴瘤, 血液系统恶性肿瘤
Monoclonal antibody B43 Genistein-conjugate临床一期University of Minnesota, 百时美施贵宝急性淋巴细胞白血病, 非霍奇金淋巴瘤详情
DI-B4DI-B4临床一期Cancer Research UK, 默克雪兰诺B细胞淋巴瘤, 慢性淋巴细胞白血病详情
C-CAR011临床一期上海赛比曼生物科技有限公司急性淋巴细胞白血病, 非霍奇金B细胞淋巴瘤详情
JCAR-017JCAR-017临床二期弗莱德哈钦森癌症研究中心, Juno Therapeutics, 西雅图儿研所, 斯隆-凯特琳癌症中心, 新基白血病, 非霍奇金淋巴瘤详情
EBV-CTL (Atara/MSKCC)EBV-CTL-Atara-MSKCC临床前斯隆-凯特琳癌症中心, Atara BiotherapeuticsEBV相关移植后淋巴组织增生性疾病
AMG-729XmAb-5871; AMG-729临床二期Xencor自身免疫疾病, 系统性红斑狼疮, 类风湿性关节炎详情
因诺卡替-19细胞临床申请深圳因诺免疫有限公司淋巴细胞性白血病
DuvortuxizumabJNJ-64052781; MGD-011临床一期MacroGenics, 杨森套细胞淋巴瘤, 弥漫大B细胞淋巴瘤, 慢性淋巴细胞白血病, 血液系统恶性肿瘤, 滤泡性淋巴瘤, 恶性肿瘤详情
ADCT-402ADCT-402临床一期ADC Therapeutics急性淋巴细胞白血病, 非霍奇金淋巴瘤详情
CAR-CD19 T cell therapyCT-032,CT032; CT 032临床一期科济生物医药(上海)B细胞淋巴瘤, 白血病详情
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology)临床申请上海优卡迪生物医药科技急性淋巴细胞白血病, 中枢神经系统白血病
H-31970-SAGANH-31970-SAGAN临床一期贝勒医学院, 德克萨斯儿童医院, 卫理公会医院慢性淋巴细胞白血病, 急性淋巴细胞白血病, 非霍奇金淋巴瘤
CD19-CAR (Anke Biotechnology)临床申请安科生物急性淋巴细胞白血病

消息提示

请输入您的联系方式,再点击提交!

确定